Free Access
Méd. Intensive Réa.
Volume 27, Number 6, Novembre 2018
Néphrologie et métabolisme
Page(s) 548 - 557
Section Mise au point / Update
Published online 11 December 2018
  • Cirrhose [Internet]. Inserm. [cited 2018 Jul 21]. Available from: [Google Scholar]
  • Piton G, Chaignat C, Giabicani M, Cervoni JP, Tamion F, Weiss E, Paugam-Burtz C, Capellier G, Di Martino V, (2016) Prognosis of cirrhotic patients admitted to the general ICU. Ann Intensive Care Ann Intensive Care: 94 [Google Scholar]
  • McPhail MJW, Parrott F, Wendon JA, Harrison DA, Rowan KA, Bernal W, (2018) Incidence and outcomes for patients with cirrhosis admitted to the United Kingdom critical care units. Crit Care Med 6: 705–712 [Google Scholar]
  • O’Brien AJ, Welch CA, Singer M, Harrison DA, (2012) Prevalence and outcome of cirrhosis patients admitted to UK intensive care: a comparison against dialysis-dependent chronic renal failure patients. Intensive Care Med 38: 991–1000 [CrossRef] [PubMed] [Google Scholar]
  • McPhail MJW, Shawcross DL, Abeles RD, Chang A, Patel V, Lee GH, Abdulla M, Sizer E, Willars C, Auzinger G, Bernal W, Wendon JA, (2015) Increased survival for patients with cirrhosis and organ failure in liver intensive care and validation of the chronic Liver Failure-Sequential Organ Failure Scoring System. Clin Gastroenterol Hepatol 13: 1353–1360.e8 [CrossRef] [PubMed] [Google Scholar]
  • Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R, (2004) Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 40: 652–659 [CrossRef] [PubMed] [Google Scholar]
  • de Franchis R, Baveno V Faculty, (2010) Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53: 762–768 [CrossRef] [PubMed] [Google Scholar]
  • de Franchis R, Baveno VI Faculty, (2015) Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 63: 743–752 [CrossRef] [PubMed] [Google Scholar]
  • Nadim MK, Durand F, Kellum JA, Levitsky J, O’Leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS, (2016) Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol 64: 717–735 [CrossRef] [PubMed] [Google Scholar]
  • Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT; National Heart ; Lung, and Blood Institute ARDS Clinical Trials Network, (2004) Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 351: 327–336 [CrossRef] [PubMed] [Google Scholar]
  • Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group, (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368–1377 [CrossRef] [PubMed] [Google Scholar]
  • Garcia-Tsao G, Parikh CR, Viola A, (2008) Acute kidney injury in cirrhosis. Hepatology 48: 2064–2077 [CrossRef] [PubMed] [Google Scholar]
  • Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR, (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33: 464–470 [CrossRef] [PubMed] [Google Scholar]
  • Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, Kim WR, (2001) MELD and PELD: application of survival models to liver allocation. Liver Transplant 7: 567–580 [CrossRef] [Google Scholar]
  • Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R; United Network for Organ Sharing Liver Disease Severity Score Committee, (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124: 91–96 [CrossRef] [PubMed] [Google Scholar]
  • Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G, (2015) Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 62: 968–974 [CrossRef] [PubMed] [Google Scholar]
  • Khwaja A, (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120: c179–c184 [CrossRef] [PubMed] [Google Scholar]
  • Wong F, Angeli P, (2017) New diagnostic criteria and management of acute kidney injury. J Hepatol 66: 860–861 [CrossRef] [PubMed] [Google Scholar]
  • Arroyo V, Terra C, Ginès P, (2007) Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 46: 935–946 [CrossRef] [PubMed] [Google Scholar]
  • Piano S, Tonon M, Angeli P, (2018) Management of ascites and hepatorenal syndrome. Hepatol Int 12: 122–134 [CrossRef] [PubMed] [Google Scholar]
  • Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL–CLIF Consortium, (2013) Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144: 1426–1437, 1437.e1-9 [CrossRef] [PubMed] [Google Scholar]
  • Huelin P, Piano S, Solà E, Stanco M, Solé C, Moreira R, Pose E, Fasolato S, Fabrellas N, de Prada G, Pilutti C, Graupera I, Ariza X, Romano A, Elia C, Cárdenas A, Fernández J, Angeli P, Ginès P, (2017) Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol 15: 438–445.e5 [CrossRef] [PubMed] [Google Scholar]
  • Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, Graupera I, Ariza X, Pereira G, Alfaro I, Cárdenas A, Fernández J, Poch E, Ginès P, (2013) A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol 59: 474–481 [CrossRef] [PubMed] [Google Scholar]
  • Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath P, (2018) Hepatorenal syndrome. Nat Rev Dis Primer Nat Rev Dis Primer: 23 [CrossRef] [Google Scholar]
  • Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, Solá E, Pereira G, Marinelli M, Pavesi M, Fernández J, Rodés J, Arroyo V, Ginès P, (2011) Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 140: 488–496.e4 [CrossRef] [PubMed] [Google Scholar]
  • Arora V, Maiwall R, Vijayaraghavan R, Jindal A, Saggere Muralikrishna S, Kumar G, Jain P, Sarin SK, (2018) Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology (doi: 10.1002/hep.30208. [Epub ahead of print]) [Google Scholar]
  • European Association for the Study of the Liver. Electronic address:; European Association for the Study of the Liver, (2018) EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 69: 406–460 [CrossRef] [PubMed] [Google Scholar]
  • Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G, (2015) Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 64: 531–537 [CrossRef] [PubMed] [Google Scholar]
  • Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, Pereira G, Poca M, Sánchez J, Guevara M, Soriano G, Alessandria C, Fernández J, Arroyo V, Ginès P, (2014) Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol 60: 955–961 [CrossRef] [PubMed] [Google Scholar]
  • Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group, (2011) Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 55: 315–321 [CrossRef] [PubMed] [Google Scholar]
  • Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Davenport A, Jalan R, Ronco C, Genyk Y, Arroyo V, (2011) Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 60: 702–709 [CrossRef] [PubMed] [Google Scholar]
  • Tripathi D, Hayes PC, (2014) Beta-blockers in portal hypertension: new developments and controversies. Liver Int 34: 655–667 [CrossRef] [PubMed] [Google Scholar]
  • Arroyo V, García-Martinez R, Salvatella X, (2014) Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 61: 396–407 [CrossRef] [PubMed] [Google Scholar]
  • Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D, (1998) Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29: 565–570 [CrossRef] [PubMed] [Google Scholar]
  • Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, Laggner A, Grimm G, Gerbes AL, (1991) Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 101: 1060–7 [CrossRef] [PubMed] [Google Scholar]
  • Valla D, Lee SS, Moreau R, Hadengue A, Sayegh R, Lebrec D, (1985) Effects of glypressin on the splanchnic and systemic circulation in patients with cirrhosis. Gastroenterol Clin Biol 9: 877–880 [PubMed] [Google Scholar]
  • Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P; Terlipressin Study Group, (2008) A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360–8 [CrossRef] [PubMed] [Google Scholar]
  • Paugam-Burtz C, Levesque E, Louvet A, Thabut D, Amathieu R, Bureau C, Camus C, Chanques G, Faure S, Ferrandière M, Francoz C, Galbois A, Gustot T, Ichai C, Ichai P, Jaber S, Lescot T, Moreau R, Roullet S, Saliba F, Thevenot T, Velly L, Weiss E, (2018) Liver failure in ICU. [Google Scholar]
  • Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators, (2008) Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 134: 1352–1359 [CrossRef] [PubMed] [Google Scholar]
  • Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P, (2016) Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology 63: 983–992 [CrossRef] [PubMed] [Google Scholar]
  • Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A, (2007) Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 47: 499–505 [CrossRef] [PubMed] [Google Scholar]
  • Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, Sharma AK, Choudhary NS, Chawla Y, Nain CK, (2012) Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 56: 1293–1298 [CrossRef] [PubMed] [Google Scholar]
  • Sharma P, Kumar A, Shrama BC, Sarin SK, (2008) An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 103: 1689–1697 [Google Scholar]
  • Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS, Singh S, (2017) Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2: 94–102 [CrossRef] [PubMed] [Google Scholar]
  • Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA, (2018) Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. Indian J Gastroenterol 37: 424–429 (doi: 10.1007/s12664-018-0876-3. Epub 2018 Sep 3) [Google Scholar]
  • Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome, (2015) Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 62: 567–574 [CrossRef] [PubMed] [Google Scholar]
  • Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O’Leary JG, Ganger D, Jamil K, Pappas SC; REVERSE Study Investigators, (2016) Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 150: 1579–1589.e2 [CrossRef] [PubMed] [Google Scholar]
  • Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V, (2007) Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56: 1310–1318 [PubMed] [Google Scholar]
  • Allegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI, (2018) Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. Clin J Am Soc Nephrol CJASN 13: 16–25 [CrossRef] [Google Scholar]
  • Zhang Z, Maddukuri G, Jaipaul N, Cai CX, (2015) Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care 30: 969–974 [Google Scholar]
  • Sourianarayanane A, Raina R, Garg G, McCullough AJ, O’Shea RS, (2014) Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients. Int Urol Nephrol 46: 793–800 [CrossRef] [PubMed] [Google Scholar]
  • Staufer K, Roedl K, Kivaranovic D, Drolz A, Horvatits T, Rasoul-Rockenschaub S, Zauner C, Trauner M, Fuhrmann V, (2017) Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int 37: 843–850 [CrossRef] [PubMed] [Google Scholar]
  • Lenhart A, Hussain S, Salgia R, (2018) Chances of renal recovery or liver transplantation after hospitalization for alcoholic liver disease requiring dialysis. Dig Dis Sci 63: 2800–2809 (doi: 10.1007/s10620-018-5170-9. Epub 2018 Jun 22) [CrossRef] [PubMed] [Google Scholar]
  • Durand F, Olson JC, Nadim MK, (2017) Renal dysfunction and cirrhosis. Curr Opin Crit Care 23: 457–462 [CrossRef] [PubMed] [Google Scholar]
  • Gaudry S, Hajage D, Dreyfuss D, (2016) Initiation of Renal- Replacement Therapy in the Intensive Care Unit. N Engl J Med 375: 1901–1902 [Google Scholar]
  • Vaara ST, Korhonen A-M, Kaukonen KM, Nisula S, Inkinen O, Hoppu S, Laurila JJ, Mildh L, Reinikainen M, Lund V, Parviainen I, Pettilä V; FINNAKI Study Group, (2012) Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study. Crit Care Lond Engl 16: R197 [CrossRef] [PubMed] [Google Scholar]
  • Wong F, Leung W, Al Beshir M, Marquez M, Renner EL, (2015) Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transplant 21: 300–307 [CrossRef] [Google Scholar]
  • Marik PE, Wood K, Starzl TE, (2006) The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 21: 478–82 [PubMed] [Google Scholar]
  • Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB, (1991) Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome — experience in 300 patients. Transplantation 51: 428–430 [CrossRef] [PubMed] [Google Scholar]
  • Xu X, Ling Q, Zhang M, Gao F, He Z, You J, Zheng S, (2009) Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation 87: 1514–1519 [CrossRef] [PubMed] [Google Scholar]
  • Lameire NH, Vanholder R, (2004) Pathophysiology of ischaemic acute renal failure. Best Pract Res Clin Anaesthesiol 18: 21–36 [CrossRef] [PubMed] [Google Scholar]
  • Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, Selby R, (2012) Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transplant 18: 539–548 [CrossRef] [Google Scholar]
  • Bahirwani R, Forde KA, Mu Y, Lin F, Reese P, Goldberg D, Abt P, Reddy KR, Levine M, (2014) End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. Clin Transplant 28: 205–210 [CrossRef] [PubMed] [Google Scholar]
  • Fabrizi F, Dixit V, Martin P, Messa P, (2011) Pre-transplant kidney function predicts chronic kidney disease after liver transplant: metaanalysis of observational studies. Dig Dis Sci 56: 1282–1289 [CrossRef] [PubMed] [Google Scholar]
  • Garces G, Contreras G, Carvalho D, Jaraba IM, Carvalho C, Tzakis A, Moon J, Ratnam K, Roth D, (2011) Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus. Clin Nephrol 75: 150–157 [CrossRef] [PubMed] [Google Scholar]
  • Chawla LS, Eggers PW, Star RA, Kimmel PL, (2014) Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371: 58–66 [CrossRef] [PubMed] [Google Scholar]
  • Reverter E, Escorsell A, Fernández J, (2017) Renal replacement therapy in critically ill cirrhotic patients: a challenging balance between efficacy and futility. Liver Int 37: 817–819 [CrossRef] [PubMed] [Google Scholar]
  • McPhail MJW, Auzinger G, Bernal W, Wendon JA, (2016) Decisions on futility in patients with cirrhosis and organ failure. Hepatology Hepatology: 986 [Google Scholar]
  • Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, Laleman W, Trebicka J, Elkrief L, Hopf C, Solís-Munoz P, Saliba F, Zeuzem S, Albillos A, Benten D, Montero-Alvarez JL, Chivas MT, Concepción M, Córdoba J, McCormick A, Stauber R, Vogel W, de Gottardi A, Welzel TM, Domenicali M, Risso A, Wendon J, Deulofeu C, Angeli P, Durand F, Pavesi M, Gerbes A, Jalan R, Moreau R, Ginés P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL–CLIF Consortium, (2015) Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 62: 243–252 [CrossRef] [PubMed] [Google Scholar]
  • Levesque E, Hoti E, Azoulay D, Ichaï P, Habouchi H, Castaing D, Samuel D, Saliba F, (2012) Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol 56: 95–102 [CrossRef] [PubMed] [Google Scholar]
  • Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R, (2001) Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 34: 255–61 [CrossRef] [PubMed] [Google Scholar]
  • Saliba F, Ichai P, Levesque E, Samuel D, (2013) Cirrhotic patients in the ICU: prognostic markers and outcome. Curr Opin Crit Care 19: 154–160 [CrossRef] [PubMed] [Google Scholar]
  • European Association for the Study of the Liver. Electronic address:, (2016) EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 64: 433–485 [CrossRef] [PubMed] [Google Scholar]
  • Artru F, Louvet A, Ruiz I, Levesque E, Labreuche J, Ursic-Bedoya J, Lassailly G, Dharancy S, Boleslawski E, Lebuffe G, Kipnis E, Ichai P, Coilly A, De Martin E, Antonini TM, Vibert E, Jaber S, Herrerro A, Samuel D, Duhamel A, Pageaux GP, Mathurin P, Saliba F, (2017) Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. J Hepatol 67: 708–715 [CrossRef] [PubMed] [Google Scholar]
  • Huebener P, Sterneck MR, Bangert K, Drolz A, Lohse AW, Kluge S, Fischer L, Fuhrmann V, (2018) Stabilisation of acuteon- chronic liver failure patients before liver transplantation predicts post-transplant survival. Aliment Pharmacol Ther 47: 1502–1510 [Google Scholar]
  • Thuluvath PJ, Thuluvath AJ, Hanish S, Savva Y, (2018) Liver transplantation in patients with multiple organ failures: Feasibility and outcomes. J Hepatol 69: 1047–1056 (doi: 10.1016/j.jhep.2018.07.007. Epub 2018 Jul 31) [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.